Oppenheimer downgraded Arvinas (ARVN) to Perform from Outperform.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARVN:
- Arvinas, Pfizer announce VERITAC-2 achieved primary endpoint in Phase 3 trial
- Arvinas price target lowered to $19 from $28 at Citi
- Arvinas Holding: Positive Earnings Call Highlights Growth
- Arvinas Holding Faces Legal Risks Amid Stock Price Volatility
- Arvinas Holding Company: Strategic Advancements and Strong Financial Position Drive ‘Buy’ Rating
Questions or Comments about the article? Write to editor@tipranks.com